Compare MBIN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | ANIP |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2017 | 1999 |
| Metric | MBIN | ANIP |
|---|---|---|
| Price | $52.81 | $69.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $43.67 | ★ $110.00 |
| AVG Volume (30 Days) | 123.8K | ★ 308.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | ★ 2.73 | 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $31.76 | $21.01 |
| Revenue Next Year | $3.73 | $17.59 |
| P/E Ratio | ★ $19.47 | $30.25 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $30.37 | $69.58 |
| 52 Week High | $56.87 | $99.39 |
| Indicator | MBIN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 35.89 |
| Support Level | $45.39 | $70.15 |
| Resistance Level | $54.48 | $83.20 |
| Average True Range (ATR) | 1.33 | 1.79 |
| MACD | -0.24 | -0.21 |
| Stochastic Oscillator | 32.29 | 10.32 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.